As SR11302 is a known compound with strong anti-AP-1 activity with selective binding with RARα and RARΥ, but not with RARβ and RXRα [18], it provides important evidence that the AP-1 complex may play an important role in CTC survival and, ultimately, tumor metastasis in lung cancer. Here, RARA is linked to lung carcinoma.